Acetylcholine Inhibits Platelet Activation

John A. Bennett, Sara K. Ture, Rachel A. Schmidt, Michael A. Mastrangelo, Scott J. Cameron, Lara E. Terry, David I. Yule, Craig N. Morrell, and Charles J. Lowenstein

Aab Cardiovascular Research Institute, Department of Medicine (J.A.B., S.K.T., R.A.S., M.A.M., S.J.C., C.N.M., C.J.L.) and Department of Pharmacology and Physiology (L.E.T., D.I.Y.), University of Rochester Medical Center, Rochester, New York

Received September 11, 2018; accepted February 12, 2019

ABSTRACT

Platelets are key mediators of thrombosis. Many agonists of platelet activation are known, but fewer endogenous inhibitors of platelets, such as prostacyclin and nitric oxide (NO), have been identified. Acetylcholinesterase inhibitors, such as donepezil, can cause bleeding in patients, but the underlying mechanisms are not well understood. We hypothesized that acetylcholine is an endogenous inhibitor of platelets. We measured the effect of acetylcholine or analogs of acetylcholine on human platelet activation ex vivo. Acetylcholine and analogs of acetylcholine inhibited platelet activation, as measured by P-selectin translocation and glycoprotein IIb IIIa conformational changes. Conversely, we found that antagonists of the acetylcholine receptor, such as pirenzepine, enhance platelet activation. Furthermore, drugs inhibiting acetylcholinesterase, such as donepezil, also inhibit platelet activation, suggesting that platelets release acetylcholine. We found that NO mediates acetylcholine inhibition of platelets. Our data suggest that acetylcholine is an endogenous inhibitor of platelet activation. The cholinergic system may be a novel target for antithrombotic therapies.

Introduction

Platelet activation is crucial for hemostasis and thrombosis (Ho-Tin-Noe et al., 2011; Stalker et al., 2014; Joshi and Whiteheart, 2017). A variety of agonists activate platelets in vivo, including thrombin, collagen, and ADP (Hechler et al., 1998; Boeynaems et al., 2005; Coughlin; 2005; Ghoshal and Bhattacharyya, 2014; Hisada et al., 2015). An equally important aspect of platelet biology is inhibition of activation, limiting excess thrombosis, which can otherwise lead to stroke or pulmonary embolism. Endogenous platelet inhibitors include factors released from endothelial cells, such as nitric oxide (NO) and prostacyclin (Moncada et al., 1977; Radomski et al., 1987b; Freedman et al., 1999; Jin et al., 2005).

Studies of adverse bleeding reactions to commonly used drugs can reveal novel inhibitors of platelet function (Holly and Parise, 2011). For example, a few case reports have suggested that acetylcholinesterase (AChE) inhibitors are associated with bleeding (Gareri et al., 2005; Cholongitas et al., 2006). Several clinical trials have examined the safety of donepezil, and one of these trials showed that donepezil increases the risk of bruising (Rogers et al., 1998; Tariot et al., 2001). A meta-analysis of clinical trials of AChE inhibitors shows that these drugs increase the risk of bruising by 1.5-fold compared with placebo, although this increased risk is not significant (Birks, 2006). These isolated clinical studies suggest that acetylcholine may be an endogenous inhibitor of platelet activation. For these reasons, we chose to examine the effect of acetylcholine signaling on platelet activation.

Prior work from other laboratories suggests that acetylcholine receptors (AChRs) are involved in platelet function. Human platelets express subunits of the AChR (Schedel et al., 2011). Artificial agonists of AChR stimulate calcium flux across human platelet membranes (Schedel et al., 2011). Certain agonists of AChR increase human platelet activation as measured by glycoprotein IIb IIIa (GPIIbIIIa) conformational changes and by aggregation (Schedel et al., 2011). Finally, platelets from mice lacking AChR subunit Chra7 have increased activation when stimulated by ADP (Kooijman et al., 2015). These important experimental studies suggest that acetylcholine signaling plays a role in inhibiting platelets both in vitro and in vivo.

Gaps remain in our collective knowledge pertaining to the effect of acetylcholine on platelets. The effect of acetylcholine on platelets stimulated with endogenous agonists other than ADP is not yet completely known. The effect of acetylcholine on platelet degranulation is not fully understood. The effect of endogenous acetylcholine signaling on hemostasis and thrombosis is not well defined. The expression of genes involved in acetylcholine signaling in human

ABBREVIATIONS: AChE, acetylcholinesterase; AChR, acetylcholine receptors; BAPA, 1,2-bis(o-aminophenoxy)ethane-N,N’N,N’-tetraacetic acid; CHRN7, cholinergic receptor neuronal nicotinic α polypeptide 7; FITC, fluorescein isothiocyanate; GPIIbIIIa, glycoprotein IIb IIIa; l-NAME, l-nitroarginine methyl ester; NO, nitric oxide; NOS3, nitric oxide synthase isofrom 3; P2Y12, purinergic receptor P2Y; TRAP, thrombin receptor activating peptide 6.
platelets is not fully described, and the mechanisms through which clinical drugs targeting acetylcholine affect bleeding in humans has not yet been explored. Determining the role that acetylcholine signaling plays in inhibition of platelet function may help clinicians avoid the toxicity of drugs that target the parasympathetic nervous system and may help us uncover new pathways that inhibit platelet function.

Materials and Methods

Human Platelet Collection. Human blood collection was performed as previously described using protocols approved by the Institutional Review Board at the University of Rochester Medical Center (IRB Protocol RSRB00028659) (Cameron et al., 2015). Normal healthy blood donors were recruited. Subjects were excluded if they had used aspirin or any nonsteroidal anti-inflammatory agent within 10 days before the blood draw. Blood was collected by venipuncture into sodium citrate anticoagulant tubes. Whole blood was centrifuged at 180g for 15 minutes to isolate the top layer of platelet-rich plasma, which was diluted 1:20 in room temperature Tyrode’s buffer (134 mM NaCl, 2.9 mM KCl, 12 mM NaHCO3, 0.34 mM Na2HPO4, 20 mM HEPES, pH 7.0, 5 mM glucose, 0.35% bovine serum albumin) and dispensed in 100-μl volumes for treatment with various drugs.

Platelet Drug Treatment. Human platelets were suspended in Tyrode’s buffer and placed into microcentrifuge tubes. Drugs were added, and the platelets were incubated for 15 minutes at room temperature. To some samples, L-nitroarginine methyl ester (L-NAME) was added first and incubated for 15 minutes; then carbachol (Sigma-Aldrich, St. Louis, MO) or acetylcholine (Sigma-Aldrich) was incubated for 15 minutes, and thrombin receptor activating peptide 6 (TRAP) (Tocris Bioscience, Oxfordshire, UK) or thrombin (Cayman Chemical Company, Ann Arbor, MI) was incubated for 15 minutes. Platelets were first treated for 15 minutes with 1,2-bis(o-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid (BAPTA) and trifluoperazine (Sigma-Aldrich) for some experiments. For experiments involving cholinesterase inhibition, platelets were pretreated with donepezil for 15 minutes before stimulation. For experiments with nAChR-selective agonist PNU-282987, platelets were pretreated for 15 minutes with PNU before stimulation. For calcium flux experiments with Fura-2 AM, platelet-rich plasma was loaded with Fura-2 AM at 5 μM for 1 hour at 37°C and then further prepared as described to yield platelets loaded with Fura-2. HEK293 cells were also loaded as a positive control. Cells were analyzed on a FACSstation 3 (Molecular Devices, San Jose, CA) for the 340/380 Fura-2 AM ratio.

Detection of Platelet Activation by Flow Cytometry. Phycoerythrin-labeled antibody to CD62P (P-selectin) (Becton Dickinson, San Jose, CA) at a dilution of 1:100 was added to platelets after stimulation or drug treatment of 30 minutes. Platelets were then fixed in 1% formalin. Surface P-selectin was measured by flow cytometry (LSRII; Becton Dickinson). To detect conformational changes in GPIIbIIa, fluorescein isothiocyanate (FITC)-fibrinogen (Abcam) was added for 30 minutes, and platelets were analyzed by flow cytometry. We have previously used these techniques to measure platelet activation (Zhu et al., 2014).

Quantification of cGMP Levels by Enzyme-Linked Immunosorbent Assay. Platelets were treated and stimulated as described. The reactions were stopped, and cells were lysed by the addition of HCl to a final concentration of 0.1 M. Samples were cleared by centrifugation (14,000 rpm) for 20 minutes. Samples were then analyzed for cGMP content using a commercially available enzyme-linked immunosorbent assay (Cayman Chemical Company).

Statistical Analyses. Data were analyzed by two-tailed Student’s t test for comparison of two groups and by Bonferroni corrected two-way analysis of variance to compare means of three or more groups. Statistical significance was defined as P < 0.05.

Results

Acetylcholine Receptors Regulate Platelet Activation. Since patients taking acetylcholine inhibitors have an increased risk of bleeding, we hypothesized that increased acetylcholine signaling directly inhibits platelet activation. To test this hypothesis, we first analyzed the effect of carbachol, an analog of acetylcholine, on platelet activation. We treated human platelets with increasing concentrations of carbachol and then stimulated the platelets with the thrombin receptor agonist thrombin receptor activating peptide 6 (TRAP). Carbachol inhibits activation of human platelets in a dose-dependent manner (Fig. 1A). We next explored the effect of acetylcholine on platelet activation. Acetylcholine inhibits TRAP activation of human platelets in a dose-responsive manner by >25% of maximal stimulation (Fig. 1B), and acetylcholine inhibits platelet activation over a range of TRAP doses (Fig. 1C).

We tested the effect of acetylcholine signaling on platelets stimulated with different agonists, including TRAP, which activates the thrombin receptor protease activated receptor 1; ADP, which activates the ADP receptor purinergic receptor P2Y (P2Y12); U44619, which activates the thromboxane receptor TP; and convulxin, which activates the collagen receptor glycoprotein VI. Carbachol inhibits platelet activation by other agonists (Fig. 1, D–F).

The preceding data show that acetylcholine inhibits α-granule release. Next, we tested the effect of acetylcholine signaling on other aspects of platelet activation, namely, dense granule secretion and GPIIbIIa conformational changes. We found that the acetylcholine analog carbachol decreases dense granule exocytosis measured by release of ATP (Fig. 1G) and inhibits GPIIbIIa activation measured by FITC-fibrinogen binding (Fig. 1H). Furthermore, endogenous acetylcholine has the same effect (as shown when the acetylcholine esterase inhibitor pyridostigmine is added) (Fig. 1G).

We also tested the effect of the nicotinic receptor agonist PNU-282987 on platelet activation. We found that PNU inhibits thrombin-induced platelet exposure of P-selectin (Fig. 1I) and GPIIbIIa activation (Fig. 1J).

Taken together, these data suggest that stimulation of the acetylcholine receptor inhibits platelet activation as measured by three separate functions: α-granule release, dense granule release, and GPIIbIIa activation.

Endogenous Acetylcholine Inhibits Platelet Activation. Whereas acetylcholine signaling inhibits platelet activation, the potential source of acetylcholine in vivo remains unclear. We hypothesized that platelets release acetylcholine, which inhibits platelet activation in an autocrine or paracrine manner. We treated platelets with the AChE inhibitor pyridostigmine bromide before activation and observed that inhibition of AChE decreases platelet activation (Fig. 2A), consistent with the idea that pyridostigmine bromide inhibits AChE, increasing the amount of acetylcholine released by platelets that is available to signal through the acetylcholine receptor. We then confirmed that pancuronium bromide, which antagonizes the acetylcholine receptor, enhances platelet

Study Approval. Human blood collection was performed using protocols approved by the Institutional Review Board at the University of Rochester Medical Center.
activation (Fig. 2B). We tested the effect of these compounds on platelet GPIIbIIIa activation using FITC-fibrinogen and observed that agonism of acetylcholine receptors inhibits, and antagonism of acetylcholine receptors enhances, binding (Fig. 2C).

Patients who take donepezil may have an increased risk of bleeding (Rogers et al., 1998; Tariot et al., 2001; Cholongitas et al., 2006). Since donepezil is an acetylcholinesterase inhibitor, we hypothesized that donepezil inhibits platelet activation. To test this hypothesis, we treated platelets with donepezil hydrochloride and then stimulated them with TRAP. Donepezil inhibited platelet activation (Fig. 2D). These data are consistent with the hypothesis that endogenous acetylcholine released from platelets inhibits platelet activation.

Collectively, these data suggest platelets can release acetylcholine, which limits activation, and endogenous AChE blunts the extent of endogenous acetylcholine signaling.

Nitric Oxide Mediates Acetylcholine Inhibition of Platelet Activation. We next explored the mechanism through which acetylcholine signaling inhibits platelet activation. AChRs increase the synthesis of NO in endothelial cells (Zuccolo et al., 2017). Platelets express nitric oxide synthase isoform 3 (NOS3) (Sase and Michel, 1995). We proposed that nitric oxide mediates acetylcholine inhibition of platelets. To test our idea, we treated human platelets with an inhibitor of nitric oxide synthase, L-nitroarginine methyl ester (L-NAME), and then stimulated with TRAP and analyzed for surface expression of P-selectin (n = 4 ± S.D., *P < 0.05 for TRAP vs. TRAP + carbachol). Carbachol inhibits platelet activation by ADP (E). Carbachol inhibits platelet activation by U46619. (F) Carbachol inhibits platelet activation by convulxin. For (D–G), isolated human platelets were treated with PBS or 10 nM carbachol, then stimulated with various agonists, and analyzed via flow cytometry (n = 4 ± S.D., *P < 0.05 for agonist vs. agonist + carbachol). (G) Carbachol inhibits platelet-dense granule release. Platelets were isolated and treated with 10 nM carbachol, 100 μM pyridostigmine bromide or 100 nM pancuronium bromide, and then stimulated with PBS or TRAP and analyzed for surface expression of P-selectin (n = 4 ± S.D., *P < 0.05 for TRAP vs. TRAP and indicated compound). (H) Carbachol inhibits GPIbIIIa activation as measured by FITC-fibrinogen binding to platelets. Platelets were isolated and treated with 10 nM carbachol and then stimulated with the indicated concentrations of TRAP and analyzed for surface expression of P-selectin (n = 4 ± S.D., *P < 0.05 for TRAP vs. TRAP + carbachol). (I) Treatment with the nAChR α7-selective agonist PNU-282987 inhibits P-selectin exposure. Platelets were treated with PNU-282987 at the indicated concentrations, then stimulated with TRAP6, and analyzed for surface expression of P-selectin (P < 0.05 for TRAP6 + vehicle vs. TRAP6 + indicated concentration of PNU). (J) PNU inhibits GPIIbIIIa activation. Platelets were treated with PNU-282987 at the indicated concentrations, then stimulated with TRAP6, and analyzed for activation of GPIIbIIIa as described (P < 0.05 for TRAP6 + vehicle vs. TRAP6 + indicated concentration of PNU).
found that L-NAME inhibits the effects of acetylcholine on platelets in a dose-dependent manner (Fig. 3C). Since calcium signaling can regulate NOS activation, we explored a calcium signaling pathway in platelets. First, carbachol increases intracellular calcium levels in platelets (Fig. 3D). Second, the calcium chelator BAPTA blocks the ability of carbachol to inhibit platelets (Fig. 3E). Finally, calmodulin is important for acetylcholine inhibition of platelet activation (Fig. 3F). Taken together, our data suggest that NO mediates acetylcholine inhibition of platelets via a calcium-calmodulin–dependent mechanism.

**Discussion**

The major finding of our study is that acetylcholine inhibits platelet activation. Acetylcholine signals through the AChR, increasing NO levels and inhibiting platelet activation. Acetylcholine inhibits activation of platelets from humans by >15%. Taken together, our results suggest that AChR activation is a potential endogenous inhibitory pathway that prevents platelet activation.

Two types of AChRs have been described: muscarinic, which are G-protein–coupled receptors, and nicotinic, which are ligand-gated ion channels (Itier and Bertrand, 2001; Beker et al., 2003). Nicotinic AChRs are composed of five subunits in different combinations, including α, β, δ, ε, and γ subunits (Mishina et al., 1986; Unwin, 2005; Morales-Perez et al., 2016). The precise nature of the AChR in human platelets is not yet defined. Further research is needed to identify the subtypes of acetylcholine receptor and their various functions on platelets.

We have shown that NO mediates acetylcholine inhibition of platelets. Others have demonstrated that platelets express NOS3 and synthesize NO (Radomski et al., 1990a,b; Sase and Michel, 1995). Prior work has shown that NO inhibits platelet adhesion, activation, and aggregation (Radomski et al., 1987a,b,c; Freedman et al., 1999; Gkaliagkousi et al., 2007). For example, we showed that NO inhibits platelet exocytosis (Matsushita et al., 2003). Others have shown that activators of NO can inhibit platelet function (Doni et al., 1991; Liu et al., 2015). Our work extends these prior studies and shows that calcium-calmodulin signaling, and NOS activity, mediates acetylcholine inhibition of platelet activation. Our work also suggests that diseases or drugs that change NO production may affect platelet activation.

Acetylcholine inhibits activation of platelets by multiple agonists (Fig. 1). Although both PAR1 and P2Y12 are GPCR, they signal through different intracellular messenger pathways (Jin et al., 1998; Boeynaems et al., 2005; Ramachandran et al., 2017; Sanchez Centellas et al., 2017). Convulxin signals through glycoprotein IV (Marlas et al., 1983; Niedergang et al., 2000). Although these pathways ultimately converge to stimulate platelet activation, as measured by conformational changes in GPIIbIIIa, the prior signaling events are different and might be differentially susceptible to NO. Some clinical drugs take advantage of pathway specificity for platelet activation. For example, ticagrelor inhibits platelet activation by inhibiting ADP signaling through the P2Y12 receptor but not through other receptors (Goel, 2013; Patel et al., 2013; von Kugelgen, 2017).

We found that carbachol, an analog of acetylcholine, has a much stronger effect on platelet activation, inhibiting P-selectin translocation by >90% (Fig. 1A). This is likely due to poor hydrolysis of carbachol by AChE or
butyrylcholinesterase. Thus, exogenous agonists like carbachol have a powerful effect on platelet activation, but endogenous agonists such as acetylcholine have a more modest inhibitory effect on platelet activation, suggesting a role for endogenous acetylcholine as a novel mechanism to limit aberrant platelet activation.

Our work extends prior research on cholinergic signaling in platelets. Others have shown that agonists of AChR increase human platelet activation ex vivo as measured by GPIIbIIIa conformational changes and by aggregation induced by ADP (Schedel et al., 2011). We show that acetylcholine itself inhibits platelet degranulation (Fig. 1B), and PNU-282987 inhibits P-selectin externalization and inhibits GPIIbIIIa activation (Fig. 3, G–H). This finding confirms our hypothesis that acetylcholine signaling inhibits PAR-1–induced platelet activation. The difference between our work and that of Schedel et al. can potentially be explained by the choice of agonist. Supporting both our studies and hypothesis, others have shown that platelets from mice lackingChrna7 have increased aggregation when stimulated by ADP ex vivo (Kooijman et al., 2015).

Our study has several limitations that suggest future studies. We have not yet defined the composition of the acetylcholine receptor on platelets, and we have not identified the role of all acetylcholine subunits in mediating platelet inhibition. Another limitation is that we have indirect evidence that platelets store acetylcholine in their granules since AChE inhibitors boost platelet inhibition, but we have not directly measured acetylcholine inside platelet granules.

Our studies have pharmacologic relevance to humans. We show that donepezil inhibits platelet activation ex vivo at a concentration between 5 and 50 μM (Fig. 2D). This matches the concentration of donepezil of 47 μM in the serum of humans taking donepezil as a treatment of Alzheimer disease (Hefner et al., 2015). Reports in the literature suggest that drugs targeting the acetylcholine signaling pathway have modest effects on hemostasis; for example, donepezil increases bruising by about 2% more than does placebo (Birks, 2006). Another recent trial showed a benefit of AChE inhibitors for reducing the incidence of acute coronary syndrome in patients with dementia by 17% (Wu et al., 2015). Dementia patients frequently have comorbidities such as diabetes with an elevated risk of thrombosis, so giving these patients more refined and targeted AChE inhibitors may be clinically useful. Our data support our proposal that drugs that target AChE can promote bleeding in humans and may explain why donepezil is associated with hemostatic abnormalities in humans.
Our study also has therapeutic implications for the management of thrombosis. Our data suggest that drugs targeting acetylcholine receptor subunits might inhibit thrombosis. Furthermore, our data suggest that drugs increasing acetylcholine signaling will increase the risk of bleeding and bruising in patients.

Acknowledgments
We thank Leisha Machin, Gary Vincelli, Jackie Stephens, and Jackie Velasquez for technical and administrative support during this project.

Authorship Contributions
Participated in research design: Bennett, Morrell, Cameron, Lowenstein
Performed data analysis: Bennett, Schmidt
Wrote or contributed to the writing of the manuscript: Bennett, Lowenstein, Morrell, Cameron

References

Acetylcholine Inhibits Platelet Activation

187

Acknowledgments
We thank Leisha Machin, Gary Vincelli, Jackie Stephens, and Jackie Velasquez for technical and administrative support during this project.

Authorship Contributions
Participated in research design: Bennett, Morrell, Cameron, Lowenstein
Performed data analysis: Bennett, Schmidt
Wrote or contributed to the writing of the manuscript: Bennett, Lowenstein, Morrell, Cameron

References


